Cord mesenchymal stem cell therapy - Beike Biotechnology

Drug Profile

Cord mesenchymal stem cell therapy - Beike Biotechnology

Alternative Names: Human umbilical cord mesenchymal stem cells (hUC-MSC) - Beike Biotechnology; UC-MSC; UC-MSCT; Wharton's Jelly-derived mesenchymal stem cells (WJMSC) - Beike Biotechnology

Latest Information Update: 14 Jan 2016

Price : $50

At a glance

  • Originator Beike Biotechnology
  • Developer Beike Biotechnology; Chinese PLA General Hospital
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements; Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Duchenne muscular dystrophy; Multiple sclerosis; Myocardial infarction; Spinocerebellar degeneration; Systemic lupus erythematosus
  • No development reported Primary ovarian insufficiency

Most Recent Events

  • 15 Jul 2015 Safety and efficacy data from a phase II trial in patients with Acute Myocardial Infarction released by Beike Biotechnology
  • 13 May 2014 Efficacy and adverse events data from a phase I/II trial in Systemic lupus erythematosus released by Beike Biotechnology ,
  • 13 May 2014 Phase-II clinical trials in Systemic lupus erythematosus in China (IV) before May 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top